Healthcare Industry News: Elekta
News Release - October 27, 2010
Calypso Medical Initiates First Clinical Study Using Real-Time Tracking During Lung Cancer RadiotherapySite of world’s first heart transplant now pioneers use of revolutionary technology for difficult-to-treat lung cancer tumors
SEATTLE--(Healthcare Sales & Marketing Network)-- Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, today announced the initiation of the first clinical study to evaluate the use of the Calypso® System for tracking lung cancer tumors during radiation delivery, including a new design of the Company’s implantable Beacon® transponder. The initial clinical site, Tygerberg Hospital, is affiliated with the University of Stellenbosch, a leading research institution in South Africa located just outside of Cape Town, the same city where the world’s first heart transplant took place in 1967. The first implantation of the proprietary anchored Beacon transponders in a patient was performed by Professor C.T. Bolliger, Director of Respiratory Research and Co-Chairman of the Division of Pulmonology at the University of Stellenbosch.
To accommodate use in lung cancer tumors, the Beacon transponders have been designed to include an anchoring feature that provides stability in the airways of the lung. Currently cleared by the U.S. Food and Drug Administration (FDA) for permanent implantation in the prostate by way of an introducer needle, a delivery system was engineered to allow for implantation in the lung using a standard bronchoscope and proprietary delivery catheter.
“The implantation of the three anchored Beacon transponders took only twenty minutes and when combined with the Calypso System, will provide my colleagues in radiation oncology precise information about the location of the tumor,” said Professor Bolliger. “Lung tumors move faster than any other tumors in the body so they are particularly difficult to treat using radiotherapy. With Calypso’s ability to track this high-velocity repetitive motion, treatment options for lung cancer patients may expand to include earlier and more aggressive radiation treatment.”
The goal of radiation therapy is to focus the radiation beam on the tumor while avoiding the irradiation of surrounding healthy tissue which may cause serious side effects. To account for the motion associated with lung tumors, a treatment margin or envelope of healthy tissue is added around the tumor, which includes all of the possible directions in which the tumor can move as the patient breathes. In order to keep the envelope of healthy tissue being irradiated as small as possible, physicians must be able to accurately and precisely track the location of the tumor. Calypso’s technology provides physicians with this information continuously throughout each treatment session. As a result, more radiation is delivered to the tumor which may improve outcomes, and less radiation is delivered to healthy tissue which may lower the incidence of side effects.
“The five-year survival rate for lung cancer is dismal at just sixteen percent and it has improved little in the past 25 years,” said Dr. Gerald E. Paris, MB ChB, Senior Lecturer, Stellenbosch University and Senior Specialist in Radiation Oncology, Tygerberg Hospital. “In order to expand and develop curative high dose radiation therapy delivery in patients for whom surgery is undesirable or impossible, more accurate real-time tracking is essential. Calypso’s real-time tumor tracking during respiratory motion permits radiation therapy in significantly more patients who might otherwise be unable to tolerate treatment due to the development of side effects. We’ve never had real-time tracking information and we are excited to use it to explore new treatment paradigms that may improve the outlook for lung cancer patients.”
According to the International Agency for Research on Cancer, lung cancer has been the most common cancer in the world for several decades. In 2008, the most recent year for which statistics are available, lung cancer accounted for 1.38 million deaths worldwide and was the most common cause of death from cancer.1 Common side effects from radiation therapy include skin irritation, shortness of breath, coughing, fatigue and esophagitis. As the incidence of side effects decreases, the costs associated with treating those side effects also declines. Real-time tracking may permit a clinically significant reduction in side effects, thereby increasing treatment tolerance and enabling delivery of the full radiation dose for more effective treatment.
“The initiation of this clinical study is an important milestone in our vision to leverage Calypso’s technology to additional body sites where radiation delivery is severely hampered by the inability to manage tumor motion,” said Edward Vertatschitsch, Interim Chief Executive Officer of Calypso Medical. “We are extremely excited to be at this juncture where we are joining our years of development effort with lung cancer radiotherapy, a frontier with an unmet clinical need. We are hopeful that our real-time tracking technology will increase the number of patients in whom radiation can become a safer alternative by allowing the clinician to address the high degree of movement exhibited by lung tumors.”
The Calypso System, with its GPS for the Body® technology, utilizes implanted Beacon transponders to provide precise, continuous information on the tumor location during external beam radiation therapy. In contrast to other guidance techniques, Calypso’s electromagnetic technology is the only non-ionizing guidance solution that uses internal surrogates to keep the radiation beam precisely focused on the tumor without adding unnecessary radiation.
About Calypso Medical
Calypso Medical Technologies, Inc. is a Seattle-based, privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products have received U.S. FDA 510(k) clearance and the European Union CE mark for use in the prostate and post-operative prostatic bed. The Calypso System is the only commercially available real-time tracking system for radiation therapy shown to improve patient outcomes for prostate cancer. The Company has strategic relationships with Varian Medical Systems, Siemens Healthcare, Elekta Corporation and Philips Medical. Additional information can be found at www.calypsomedical.com.
1International Agency for Research on Cancer, Globocan 2008, Lung Cancer Fact Sheet, p1.
Source: Calypso Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.